102 related articles for article (PubMed ID: 30277474)
1. E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.
Bi E; Li R; Bover LC; Li H; Su P; Ma X; Huang C; Wang Q; Liu L; Yang M; Lin Z; Qian J; Fu W; Liu YJ; Yi Q
J Clin Invest; 2018 Nov; 128(11):4821-4831. PubMed ID: 30277474
[TBL] [Abstract][Full Text] [Related]
2. Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity.
Yang L; Li S; Chen L; Zhang Y
Cancer Biol Med; 2023 Oct; 20(10):728-47. PubMed ID: 37817484
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.
Olechnowicz SWZ; Weivoda MM; Lwin ST; Leung SK; Gooding S; Nador G; Javaid MK; Ramasamy K; Rao SR; Edwards JR; Edwards CM
Sci Rep; 2019 Oct; 9(1):14189. PubMed ID: 31578352
[TBL] [Abstract][Full Text] [Related]
4. Can we change the disease biology of multiple myeloma?
Borrello I
Leuk Res; 2012 Nov; 36 Suppl 1(0 1):S3-12. PubMed ID: 23176722
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Ghose J; Viola D; Terrazas C; Caserta E; Troadec E; Khalife J; Gunes EG; Sanchez J; McDonald T; Marcucci G; Kaur B; Rosenzweig M; Keats J; Rosen S; Krishnan A; Satoskar AR; Hofmeister CC; Pichiorri F
Oncoimmunology; 2018; 7(10):e1486948. PubMed ID: 30288349
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Kinneer K; Flynn M; Thomas SB; Meekin J; Varkey R; Xiao X; Zhong H; Breen S; Hynes PG; Fleming R; Bezabeh B; Chen CT; Wetzel L; Chen R; Dimasi N; Tai YT; Anderson KC; Herbst R; Howard PW; Hurt EM; Tice DA
Leukemia; 2019 Mar; 33(3):766-771. PubMed ID: 30315237
[No Abstract] [Full Text] [Related]
8. The genetic landscape of 5T models for multiple myeloma.
Maes K; Boeckx B; Vlummens P; De Veirman K; Menu E; Vanderkerken K; Lambrechts D; De Bruyne E
Sci Rep; 2018 Oct; 8(1):15030. PubMed ID: 30301958
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
Fuchida SI; Sunami K; Matsumoto M; Okumura H; Murayama T; Miyamoto T; Otsuka E; Fujishima N; Izumi T; Tamaki S; Hiramatsu Y; Kuroda Y; Shimazaki C; Akashi K; Harada M;
Int J Hematol; 2019 Jan; 109(1):107-114. PubMed ID: 30284685
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
[TBL] [Abstract][Full Text] [Related]
11. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.
Wang Q; Zhao D; Xian M; Wang Z; Bi E; Su P; Qian J; Ma X; Yang M; Liu L; Zu Y; Pingali SR; Chen K; Cai Z; Yi Q
Blood; 2020 Nov; 136(22):2557-2573. PubMed ID: 32582913
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol Induces CD8
Ma X; Bi E; Lu Y; Su P; Huang C; Liu L; Wang Q; Yang M; Kalady MF; Qian J; Zhang A; Gupte AA; Hamilton DJ; Zheng C; Yi Q
Cell Metab; 2019 Jul; 30(1):143-156.e5. PubMed ID: 31031094
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Lipid Accumulation and Metabolism Are Required for the Differentiation and Activation of Tumor-Associated Macrophages.
Su P; Wang Q; Bi E; Ma X; Liu L; Yang M; Qian J; Yi Q
Cancer Res; 2020 Apr; 80(7):1438-1450. PubMed ID: 32015091
[TBL] [Abstract][Full Text] [Related]
14. BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.
Zhang D; Huang J; Wang F; Ding H; Cui Y; Yang Y; Xu J; Luo H; Gao Y; Pan L; Wu Y; Gong Y; Xie L; Liu Z; Qu Y; Zhang L; Liu W; Zhang W; Zhao S; Yi Q; Niu T; Zheng Y
Cell Death Dis; 2021 May; 12(5):495. PubMed ID: 33993198
[TBL] [Abstract][Full Text] [Related]
15. Role of Immune Cells and Immunotherapy in Multiple Myeloma.
Radhakrishnan V; Golla U; Kudva AK
Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672732
[TBL] [Abstract][Full Text] [Related]
16. Role of adhesion molecules in cancer and targeted therapy.
Fan C; Xiong F; Zhang S; Gong Z; Liao Q; Li G; Guo C; Xiong W; Huang H; Zeng Z
Sci China Life Sci; 2024 May; 67(5):940-957. PubMed ID: 38212458
[TBL] [Abstract][Full Text] [Related]
17. Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.
Ye W; Li M; Luo K
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37513975
[TBL] [Abstract][Full Text] [Related]
18. Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment.
Lin WH; Cooper LM; Anastasiadis PZ
Front Cell Dev Biol; 2023; 11():1137013. PubMed ID: 37255594
[TBL] [Abstract][Full Text] [Related]
19. The role of interferons in ovarian cancer progression: Hinderer or promoter?
Liu T; Li Y; Wang X; Yang X; Fu Y; Zheng Y; Gong H; He Z
Front Immunol; 2022; 13():1087620. PubMed ID: 36618371
[TBL] [Abstract][Full Text] [Related]
20. Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy.
Aldahlawi AM; Abdullah ST
J Microsc Ultrastruct; 2022; 10(3):107-113. PubMed ID: 36504589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
